Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Veredus Labs develops ‘Lab-on-Chip’ to detect and differentiate several food-borne pathogens, including Escherichia coli

Veredus Laboratories, a leading provider of molecular detection tests, and its technology partner, STMicroelectronics (NYSE: STM), today announced the successful development and deployment of VereFoodborne™, a Lab-on-Chip application that is able to detect 10 to 12 food-borne pathogens in one test, including the Shiga toxin-producing Escherichia coli (E. coli) responsible for the recent severe food poisoning outbreak in Europe.

23 Jun 2011

Veredus Lab-on-Chip application can diagnose and differentiate food-borne pathogens

Veredus Laboratories, a leading provider of molecular detection tests, and its technology partner, STMicroelectronics, today announced the successful development and deployment of VereFoodborne, a Lab-on-Chip application that is able to detect 10 to 12 food-borne pathogens in one test, including the Shiga toxin-producing Escherichia coli responsible for the recent severe food poisoning outbreak in Europe.

23 Jun 2011

Daewoong, Medivir sign distribution agreement for Xerclear in China and Hong Kong

Medivir AB, a research-based specialty pharmaceutical company focused on infectious diseases, today announced that it has signed an agreement with Daewoong Pharmaceutical Co. Ltd. to exclusively distribute Medivir's unique cold sore treatment Xerclear in China and Hong Kong.

23 Jun 2011

Mothers receiving influenza vaccination during pregnancy also protect infants

Infants born to mothers who received the influenza (flu) vaccine while pregnant are nearly 50 percent less likely to be hospitalized for the flu than infants born to mothers who did not receive the vaccine while pregnant, according to a new collaborative study by researchers at Wake Forest Baptist Medical Center and colleagues.

23 Jun 2011

Sanofi Pasteur establishes new vaccine research and development facility in Canada

Mark Lievonen, President of Sanofi Pasteur Limited, and Premier Dalton McGuinty today opened a $101 million dollar vaccine research and development facility at Sanofi Pasteur's Connaught Campus in north Toronto. This new facility establishes the Connaught Campus as the North American Centre of Excellence in analytical and bioprocessing R&D for Sanofi Pasteur globally.

23 Jun 2011

Rush scientist receives NIH grant to evaluate whether cinnamon may treat MS

A neurological scientist at Rush University Medical Center has received a grant from the National Institutes of Health (NIH) to evaluate whether cinnamon, a common food spice and flavoring material, may stop the destructive process of multiple sclerosis.

23 Jun 2011

'Copilots' for physicians in intensive care units could reduce mortality rates

Caring for patients in a medical intensive care unit in a hospital and flying a 747 are complicated tasks that require tracking thousands of important details, some of which could get overlooked. That's why the pilot has a checklist and a copilot to make sure nothing slips by.

23 Jun 2011

CSL Biotherapies statement on FDA warning letter

Today the US Food and Drug Administration (FDA) published a Warning Letter issued by its Office of Compliance and Biologics Quality to CSL Biotherapies, a division of CSL Limited. The FDA regulates the manufacture, marketing and distribution of CSL Biotherapies’ influenza vaccine, Afluria®, in the US market.

21 Jun 2011

TESARO secures $101M in Series B financing

TESARO, Inc., an oncology-focused biopharmaceutical company, today announced that it has secured $101 million in a Series B financing to advance and expand the Company's cancer product portfolio.

21 Jun 2011

U.S. FDA approves generic Levaquin for treatment of bacterial infections

The U.S. Food and Drug Administration today approved the first generic versions of Levaquin, an antibiotic approved to treat certain infections in people ages 18 and older.

21 Jun 2011

Is it safe to give babies and toddlers cough medicines?

Consumer health website, www.itsmyhealth.com.au reports that over-the-counter cold remedies can do more harm than good.

20 Jun 2011

NanoViricides plans to lease new cGMP manufacturing and lab space

NanoViricides, Inc. announced today that it will be leasing new space for cGMP production of its nanoviricides drug candidates against various viral diseases.

20 Jun 2011

Pulmatrix introduces novel iSPERSE inhaled dry powder drug delivery platform

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced the launch of iSPERSE, the company's novel inhaled dry powder drug delivery platform.

20 Jun 2011

Positive results from vismodegib Phase II study on advanced basal cell carcinoma

Genentech, a member of the Roche Group, announced today that a pivotal Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

20 Jun 2011

Genentech to present positive data from vismodegib Phase II trial on advanced BCC at EADO 2011

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that positive data are being presented by its collaborator Genentech, a member of the Roche Group, from a pivotal Phase II clinical trial conducted by Roche and Genentech of vismodegib in patients with advanced basal cell carcinoma, an often life-threatening form of skin cancer that can have disfiguring and debilitating effects.

20 Jun 2011

Mother and baby cytomegalovirus screening important to prevent consequences

According to health experts, pregnant women and newborns should be screened for a virus that causes brain damage and deafness. The study that appeared in the latest issue of The Medical Journal of Australia yesterday says hundreds of cases of cytomegalovirus (CMV) are likely being missed each year in Australia because of a lack of screening, denying babies treatment for the condition.

19 Jun 2011

FDA approves NULOJIX

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.

18 Jun 2011

Boosting immune response may cause cold-induced asthma flare-ups

People often talk about "boosting" their immunity to prevent and fight colds. Nutritional supplements, cold remedies and fortified foods claim to stave off colds by augmenting the immune system.

18 Jun 2011

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene International Sàrl announced that clinical data from a Phase II study, conducted by investigators from the MD Anderson Cancer Center in Houston, TX, evaluating the combination regimen of REVLIMID plus rituximab (R2) in untreated, advanced stage, indolent B-cell non-Hodgkin's lymphomas, were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

18 Jun 2011

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Celgene International Sarl today announced a collaboration to conduct an international randomized study to evaluate the therapeutic potential of the REVLIMID/rituximab combination regimen (R2) in patients with newly diagnosed follicular lymphoma.

17 Jun 2011

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Veredus Labs develops ‘Lab-on-Chip’ to detect and differentiate several food-borne pathogens, including Escherichia coli

Veredus Lab-on-Chip application can diagnose and differentiate food-borne pathogens

Daewoong, Medivir sign distribution agreement for Xerclear in China and Hong Kong

Mothers receiving influenza vaccination during pregnancy also protect infants

Sanofi Pasteur establishes new vaccine research and development facility in Canada

Rush scientist receives NIH grant to evaluate whether cinnamon may treat MS

'Copilots' for physicians in intensive care units could reduce mortality rates

CSL Biotherapies statement on FDA warning letter

TESARO secures $101M in Series B financing

U.S. FDA approves generic Levaquin for treatment of bacterial infections

Is it safe to give babies and toddlers cough medicines?

NanoViricides plans to lease new cGMP manufacturing and lab space

Pulmatrix introduces novel iSPERSE inhaled dry powder drug delivery platform

Positive results from vismodegib Phase II study on advanced basal cell carcinoma

Genentech to present positive data from vismodegib Phase II trial on advanced BCC at EADO 2011

Mother and baby cytomegalovirus screening important to prevent consequences

FDA approves NULOJIX

Boosting immune response may cause cold-induced asthma flare-ups

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Newsletters you may be interested in